FDA places partial clinical hold on Ph 1 ZN-c3-001 in solid tumors, Ph 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and Ph 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC) of azenosertib June 25, 2024
New Survival Data for Amezalpat (TPST-1120) in 1L HCC Study Demonstrated a Six-Month Improvement over Control Arm June 25, 2024
Truqap plus Faslodex approved in the EU for patients with advanced ER-positive breast cancer based on CAPItello-291 results June 25, 2024
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage ADC Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers June 25, 2024
SEACRAFT-2 Pivotal Ph 3 Trial of Naporafenib + Trametinib Initiated in Patients with NRAS-Mutant Melanoma June 25, 2024
FAILED TRIAL: CAPItello-290 Ph 3 trial of Truqap (capivasertib) + chemo in locally advanced, inoperable or metastatic TNBC patients with PI3KCA/AKT1/PTEN alterations did not meet the dual primary endpoints of OS improvement June 25, 2024
EMA validates extension application for SC formulation for Opdivo including liquid formulation and new strength across previously approved indications June 25, 2024
FDA Approves KEYTRUDA® + Carboplatin + Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma June 25, 2024
LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial June 25, 2024
Lead Selection for MDG2021 Announced, Expanding TCR-T KRAS Library Targeting Solid Tumors June 25, 2024
GALAXIES Lung-301 Ph 3 study of Belrestotug and Dostarlimab in 1L Unresectable Locally Advanced/Metastatic PD-L1 Selected NSCLC initiated June 25, 2024
Pivotal Ph 2 Trial of Cemacabtagene Ansegedleucel (cema-cel) as 1L Treatment in Large B-Cell Lymphoma (LBCL) patients initiated June 25, 2024
Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Ph 1/2 Clinical Trial of MB-106 Announced June 25, 2024
Data from 1-BETTER Ph 1/2 study for advanced pancreatic cancer of Natrunix + ONIVYDE/5-FU announced June 25, 2024
100% Partial Response or Better Announced in Multiple Myeloma Patients in Interim, Top-line Data from STAR-LLD Ph 1b Trial June 25, 2024
China’s NMPA approves IND for GFH375 for Ph 1/2 Clinical Trial Treating Advanced Solid Tumor Patients with KRAS G12D Mutation June 25, 2024
EU approves FRUZAQLA in Previously Treated Metastatic Colorectal Cancer Based on Results from Ph 3 FRESCO-2 Trial June 25, 2024
FDA grants Accelerated Approval to KRAZATI® (adagrasib) + Cetuximab for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic CRC June 25, 2024
